Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2013 Jun 5.
Published in final edited form as: Int J Obes (Lond). 2010 Oct;34(0 1):S47–S55. doi: 10.1038/ijo.2010.184

Adaptive thermogenesis in humans

Michael Rosenbaum 1, Rudolph L Leibel 1
PMCID: PMC3673773  NIHMSID: NIHMS470540  PMID: 20935667

Abstract

The increasing prevalence of obesity and its co-morbidities reflects the interaction of genes that favor the storage of excess calories as fat with an environment that provides ad libitum availability of calorically dense foods and encourages an increasingly sedentary lifestyle. While weight reduction is difficult in and of itself, anyone who has every lost weight will confirm that it is much harder to keep the weight off once it has been lost. The over 80% recidivism rate to pre-weight loss levels of body fatness after otherwise successful weight loss is due to the coordinate actions of metabolic, behavioral, neuroendocrine, and autonomic responses designed to maintain body energy stores (fat) at a CNS- defined “ideal”. This “adaptive thermogenesis” creates the ideal situation for weight regain and is operant in both lean and obese individuals attempting to sustain reduced body weights. Much of this opposition to sustained weight loss is mediated by the adipocyte-derived hormone “leptin”. The multiplicity of systems regulating energy stores and opposing the maintenance of a reduced body weight illustrate that body energy stores in general and obesity in particular are actively “defended” by interlocking bioenergetic and neurobiological physiologies. Important inferences can be drawn for therapeutic strategies by recognizing obesity as a disease in which the human body actively opposes the “cure” over long periods of time beyond the initial resolution of symptomatology.

Keywords: Obesity, Adaptive Thermogenesis, Thyroid, Autonomic, Weight Loss

Introduction

Western societies tend to regard obesity, and the inability of individuals to sustain weight loss, as largely self-imposed conditions which reflect a lack of “will power” related to lifestyle changes. Optimal levels of adiposity are often defined by cosmetic rather than medical considerations. However, genetic, epidemiological, and physiological studies indicate that body fatness/weight is regulated, and that the increasing prevalence of obesity in western societies reflects the interactions of genes favoring energy conservation and storage with an environment which enables access to food calories and a more sedentary lifestyle.

Throughout most of human evolution the tendency to store calories as fat would likely have conferred an advantage by enabling survival during periods of prolonged caloric restriction, as well as providing greater energy stores to nourish mother and fetus during and following pregnancy. Thus, it is likely that the human genome would be enriched for alleles of genes favoring the storage of calories as adipose tissue 1. Our current environment enables the consumption of large quantities of calorically dense foods and the maintenance of an increasingly sedentary lifestyle. Clearly not everyone has the same “genetic risk” for obesity and, regardless of any genetic proclivities, anyone will gain weight if they consume more calories than they expend. As illustrated by diet-induced obesity (DIO)-prone and DIO-resistant mouse strains 2, as well as humans3, 4, there is a heritable variability in the degree of weight gain that different individuals will experience in an adipogenic environment. This variability reflects, in part, heritable influences on how much an individual participates in such an environment by increasing energy intake and/or decreasing energy expenditure, and their metabolic responsiveness to an increase in energy intake relative to expenditure 5.

Any change in the amount of energy stored, predominantly as adipose tissue (over 100,000 kcal in a 70-kg man) but also as protein and glycogen, must reflect a difference between energy taken in as food and energy expended in various forms of metabolic and physical work (see below). If energy intake and output were not regulated by interlocking control mechanisms that work concordantly to maintain energy stores, then a very small persistent change in input relative to output would, over time, lead to substantial gain or loss of stored calories. Yet, the average U.S. adult gains only 500–1000 g of weight (approximately 2000–2500 kcal of stored energy) per year (more pronounced in older individuals, African-Americans, Native-Americans, and Hispanic-Americans) 6, despite ingestion of approximately 900,000–1,000,000 kcal/year. The remarkable constancy of body weight in this context, presumably without conscious constant calculation of how many calories are being consumed and/or expended by most individuals, suggests that energy intake and expenditure vary directly to maintain relatively stable energy stores 7.

Metabolic responses to attempts to sustain weight loss

In long-term studies of weight-reduced children and adults, 80%-90% return to their previous weight percentiles 8, while studies of those successful at sustained weight loss indicate that the maintenance of a reduced degree of body fatness will probably require a lifetime of meticulous attention to energy intake and expenditure 9, 10. The inability of most otherwise successfully weight-reduced individuals to sustain weight loss reflects the actions of potent and redundant metabolic, neuroendocrine, and autonomic systems (see below).

The responses of lean and obese individuals to experimental perturbations of body weight suggest that the magnitude of stored energy, particularly fat, is defended by central nervous system-mediated mechanisms that are similar, if not identical in lean and obese individuals. In both lean and obese individuals, there is potent “opposition” to the maintenance of reduced body weight that is achieved by coordinated regulation of energy intake and expenditure mediated by signals emanating from adipose, gastrointestinal, and endocrine tissues, and integrated by the liver and by central nervous system (see Table 1).

Table 1.

Changes in energy expenditure, autonomic nervous system function, and neuroendocrine function in subjects maintaining a reduced body weight with or without leptin “replacement” 1, 97, 99

Effects of 10% Reduced Weight Maintenance Effects of Leptin Administration to Weight-Reduced Subjects
Energy Expenditure
Twenty-four-hour energy expenditure Decreased (−15%) Reversed
Resting energy expenditure Decreased or unchanged No significant change
Thermic effect of feeding Unchanged Unchanged
Non-resting energy expenditure Decreased (−30%) Reversed
Skeletal muscle work efficiency Increased (20%) Reversed
Autonomic Function
Sympathetic Nervous System tone Decreased (−40%) Reversed
Parasympathetic Nervous System tone Increased (80%) Unchanged
Neuroendocrine Function
Thyroid stimulating hormone Decreased (−18%) Unchanged
Triiodothyronine Decreased (−7%) Reversed
Thyroxine Decreased (−9%) Reversed
Gonadotropins Decreased Reversed
Circulating Leptin Decreased (proportional to fat mass) Reversed

Energy expenditure

Maintenance of a 10% or greater reduction in body weight in lean or obese individuals is accompanied by an approximate 20%-25% decline in 24-hour energy expenditure. This decrease in weight maintenance calories is 10–15% below what is predicted solely on the basis of alterations in fat and lean mass 11, 12. Thus, a formerly obese individual will require ~300–400 fewer calories per day to maintain the same body weight and physical activity level as a never-obese individual of the same body weight and composition. Studies of individuals successful at sustaining weight loss indicate that reduced weight maintenance requires long-term lifestyle alterations 9. The necessity for these long-term changes is consistent with the observation that the reduction in twenty four hour energy expenditure (TEE) persists in subjects who have sustained weight loss for extended periods of time (6 months – 7 years) in circumstances of enforced caloric restriction in the biosphere 2 project 13, bariatric surgery 14 and lifestyle modification 15.

Twenty-four hour energy expenditure (TEE) is the sum of resting energy expenditure (REE; cardiorespiratory work and the work of maintaining transmembrane ion gradients at rest; approximately 60% of TEE), the thermic effect of feeding (TEF; the work of digestion; approximately 5–10% of TEE), and non-resting energy expenditure (NREE, energy expended in physical activity above resting; approximately 30–40% of TEE). The effects of maintenance of reduced weight on each of these compartments of energy expenditure are distinctly different. There is no significant decline in TEF following weight loss 11. Some studies 1618 report no change in REE following weight loss, while in others the maintenance of a reduced body weight is associated with modest reductions in REE accounting for about 10–15% of the decline in TEE beyond that predicted on the basis of body composition changes 11, 12, 19. The variability in study results probably reflects differences among studies in multiple factors including degree and duration of weight stability before and after weight loss as well as changes in subject fitness and time spent in physical activity following weight loss. Regardless of whether or not changes in REE account for 10–15% of the changes in TEE following weight loss, NREE is clearly the compartment of energy expenditure that is most affected by changes in body weight 11, 20 consistent with the importance of physical exercise in the successful maintenance of reduced weight 9, 21.

The pre-eminence of NREE - accounting for as much of 85–90% of the decline in TEE below predicted values in weight-reduced subjects 20, 22 could be due to declines in the actual amount of physical activity performed. In rodents, maintenance of a reduced body weight is associated with an increase, rather than decrease, in the amount of time spent in physical activity 23, probably reflecting food-seeking behavior. In-patient and out-patient studies of humans following weight loss have reported, respectively, no change or as much as a 30% increase in the amount of time that subjects spend moving each day, 11, 18 supporting the view that skeletal muscle work efficiency is increased 20 (as opposed to decreased amount of motion per se) following weight loss. Since these effects are most evident at low levels of work, i.e., those commensurate with activities of daily living, it is reasonable to infer that some of the opposition to reduced weight maintenance can be diminished by exercising at higher levels of power output 20, 24.

Studies of skeletal muscle chemomechanical efficiency (calories expended above resting per unit of power generated) in weight-reduced subjects indicate that maintenance of a reduced body weight is associated with an approximate 20% increase in skeletal muscle work efficiency at low levels of exercise, whether measured by bicycle ergometry or 31P-NMR muscle spectroscopy 20. Ergometric studies measure whole body energy expenditure during stationary cycling. Energy efficiency is expressed as kcal consumed above REE per unit of power generated. Fuel utilization (fatty acid vs. glucose oxidation) is assessed by the respiratory exchange ratio (RER, ratio of CO2 produced to O2 consumed). In 31P-NMR spectroscopy, the ratio of inorganic phosphate (Pi), which increases during exercise due to the hydrolysis of ATP, to phosphocreatine (PCr) which decreases during exercise to replenish ATP, during exercise, reflects the efficiency of muscle in generating a specific amount of power. In addition, the resting Pi reflects the relative fatty acid to glucose oxidative potential of muscle, and the phosphocreatine recovery constant (kPCr, a constant reflecting the exponential rate of PCr resynthesis following exercise as well the maximal rate of oxygen consumption by muscle) reflects the muscle glycolytic potential 20, 25. 31P-NMR spectroscopy can also be used to examine the in vivo ATP cost of single muscle contraction by measuring the PCr depletion rate following muscle stimulation in an ischemic limb (no PCr repletion until blood flow is restored) 26. Both of these methods demonstrate that the maintenance of a 10% reduced body weight is associated with an approximate 20% increase in skeletal muscle chemomechanical efficiency and an approximate 18% relative increase in the fractional use of free fatty acids as fuel during low level exercise 20, 27 (see Table 2). These results are consistent with studies of vastus lateralis muscle biopsies in which the ratio of glycolytic (phosphofructokinase, PFK) to oxidative (cytochrome oxidase) enzyme activities is significantly decreased following weight loss. The changes in these enzyme ratios are sufficient to account in statistical analyses for a significant fraction of the increased efficiency (R2=0.57, p<0.001) and free fatty acid oxidation (R2=0.31, p<0.01) that occurs during low level-exercise in weight-reduced subjects 27.

Table 2.

Studies of skeletal muscle in weight reduced subjects by ergometry, 31P-NMR spectroscopy, and analysis of vastus lateralis muscle biopsy specimens 27, 97.

Ergometry 31P-NMR spectroscopy Biopsy
Efficiency NME ↑ 20% at low level exercise. 20% ↑ (Pi/PCr) at low level exercise.
18% ↓ ATP cost/muscle contraction.
Fuel Utilization 19% ↑ in % calories used derived from FFA oxidation during low level exercise 18% ↑ Pi (FFA/glucose oxidation potential).
No change kPCr (oxidative potential)
12% ↓ PFK (glycolytic) activity, 17% ↓ PFK/COX (glycolytic/FFA oxidative activity)
No significant change in FFA oxidative enzyme activities

Abbreviations: COX, cytochrome oxidase; kPCr, phosphocreatine recovery constant; FFA, free fatty acids; NMR, nuclear magnetic resonance; PCr, phosphocreatine; PFK, phosphofructokinase; Pi, inorganic phosphate

Neuroendocrine Function

The neuroendocrine changes associated with the maintenance of a reduced body weight include increased activity of the hypothalamic-pituitary-adrenal (HPA) axis and decreased activity of the hypothalamic-pituitary-thyroid (HPT) and hypothalamic-pituitary-gonadal (HPG) axes. The hypothalamic pro-opiomelanocortin (POMC)-melanocortin-melanocortin 4 receptor (MC4R) pathway, by virtue of its constituent neuronal outflow tracts to the ANS, neuroendocrine axes, and cortical tracts subserving food intake, may provide a central nexus for the sum of the integrated effects on energy expenditure and intake that are seen following weight loss 1, 28, 29.

The importance of the HPA axis in regulating body fat stores is illustrated by the effects of adrenalectomy on genetically obese rodents. The leptin-deficient or leptin-resistant mouse is hyperphagic, hypometabolic (much like the weight-reduced human as discussed below), hypercortisolemic (unlike leptin-deficient and resistant humans), and severely obese. These phenotypes are abolished by chemical or surgical adrenalectomy 30. Hypercortisolemia results in loss of lean body mass and increases the partitioning of stored calories to fat 1.

Studies of the HPA axis in which human subjects were assessed following variable weight loss regimens and lengths of time maintaining a reduced weight have found increases 31, decreases 32, and no change 33 in indices of cortisol production following weight loss. Discrepancies among studies may reflect differences in subject populations regarding exercise, gender, age, or weight loss regimens, as well as the degree of weight stability at the time of study.

Thyroid hormone increases energy expenditure by increasing heart rate, blood pressure, muscle ATP consumption (largely by stimulating production of muscle ATPase). The thyroid hormone deficient patient is hypotensive, bradycardic, and lethargic and tends to gain weight while the hyperthyroid patient is hypertensive and tachycardic and tends to lose weight 34, 35. Both weight loss and the maintenance of a reduced body weight are associated with small but statistically significant decreases in circulating concentrations of triiodothyronine (T3) and increases in the circulating concentrations of its bioinactive enantiomer reverse T3 (rT3), suggesting that weight loss results in increased peripheral conversion of thyroxine (T4) to rT3 36. Thyroid releasing hormone (TRH)-stimulated pituitary thyroid stimulating hormone (TSH) release is not diminished during caloric restriction 37 or after weight loss 38 in humans. The lack of increase in TSH with weight loss, despite the decrease in circulating concentrations of T3, indicates that hypothalamic TRH release is decreased following weight loss. Caloric restriction and maintenance of a reduced body weight are associated with decreased circulating leptin concentrations (see below) 39. Low ambient leptin, in turn, reduces POMC production in hypothalamic neurons. Decreased hypothalmic alpha-MSH (α-MSH), a proteolytic product of POMC, results in decreased activity of hypothalamic pro-thyroid releasing hormone (pro-TRH) neurons in rats 40, thus providing a possible mechanism for the decrease in HPT axis activity following weight loss and the restoration of circulating concentrations of bioactive thyroid hormones following leptin replacement 41.

Autonomic Nervous System Function

The autonomic nervous system (both parasympathetic and sympathetic) includes major outflow tracts linking afferent biochemical signals regarding energy stores and efferent tracts regulating energy expenditure. Increased parasympathetic nervous system activity slows heart rate and decreases resting energy expenditure. The sympathetic branch of the autonomic nervous system modulates feeding behavior, directly increases heart rate, and acts directly on the thyroid gland to increase the rate of secretion of thyroid hormone 42, 43. Sympathetic denervation of the arm in humans with palmar hyperhidrosis improves skeletal muscle work efficiency 44 in arm muscles, and chemical sympathectomy attenuates leptin-mediated increases in energy expenditure in rats 45. Daily urinary norepinephrine excretion accounts for a significant proportion of the variance in energy expenditure and its subcomponents in weight stable subjects 36.

The maintenance of a reduced body weight is associated with significant declines in SNS tone (by analysis of heart rate following sequential parasympathetic and sympathetic blockade or 24-hour urinary catecholamine excretion) and increases in PNS tone 36, 43, 46. Changes in ANS tone associated with weight loss, in particular the decline in sympathetic nervous system tone, may account for a significant fraction of the hypometabolic state through direct effects on skeletal muscle, and/or indirectly via effects on circulating concentrations of thyroid hormones36, 47, 48. Thus, weight-loss mediated changes in autonomic nervous system activity may constitute a link between weight-loss associated changes in energy and neuroendocrine homeostasis.

Brown Adipose Tissue

Brown adipose tissue (BAT) allows the uncoupling of mitochondrial substrate oxidation from ATP production thereby releasing the energy of fatty acid oxidation as heat 49. This is achieved via a 32kd “uncoupling protein” (UCP1) which is present in BAT, but not in white adipose tissue (WAT). BAT has a rich sympathetic nerve and vascular supply and, in the presence of cold, weight gain, and/or sympathetic nervous stimulation in rodents or exogenous or endogenous hypercatecholaminemia in humans, BAT activity increases resulting in heat generation 50, 51 The activation of BAT is dependent upon integration of input from the sympathetic nervous system activation of adrenoreceptors (predominantly β3) 52, with activation of at least one of the thyroid hormone receptors (TR) subtypes (TRα or TRβ) 53. The leptin-sensitive declines in sympathetic nervous system activity and circulating concentrations of bioactive thyroid hormones following weight loss that are described above constitute a mechanism by which reduced obligatory and/or facultative thermogenesis by BAT could contribute to adaptive thermogenesis in humans. As little as 25gm of BAT going from a maximally active to a minimally active state following weight loss would be more than sufficient to account for the magnitude of decline in REE in weight-reduced subjects that occurs beyond that predicted solely on the basis of weight and body composition changes 54. Therefore, it is possible that a significant fraction of the unexplained variance in resting energy expenditure or in changes in resting energy expenditure following weight loss is attributable to changes in the activity or brown adipose tissue (BAT) 55.

However, while BAT is a major contributor to adaptive thermogenesis in small mammals 56, its role in thermogenesis in adult humans remains unclear. In rodents, BAT contributes to both obligatory thermogenesis (the heat produced to maintain body temperature at rest) and facultative thermogenesis (the heat produced to maintain body temperature at ambient temperatures below thermoneutrality) 53. The cold intolerance of hypothyroid rodents reflects declines in both obligatory and facultative thermogenesis by BAT 53. BAT is easily detected in rodents and clearly plays a role in non-shivering thermogenesis in human neonates.

Previous studies showed a lack of a significant presence of BAT in humans except under extreme conditions of hypercatecholaminemia 57 and, until recently, no studies have been carried out quantifying the contribution of BAT to total adaptive thermogenesis in humans. Recent advances in positive emission tomography (PET) scanning technology have allowed detailed imaging of BAT using uptake of 2-[18F]fluoro-2-desoxy-glucose (FDG) and a hybrid scanner. FDG uptake has been shown to correspond to the neck, supraclavicular, mediastinal, paraspinal, paravertebral and renal areas known to contain BAT in humans 58,59, 60 and FDG uptake in these areas (www.med.harvard.edu/JPNM/chetan/normals/brown_fat/case.html) is inhibited by β-adrenergic blockade with propranolol 6163. In a recent series of papers 54, 64, 65, several groups demonstrated the ability to detect BAT in healthy human beings with varying results as to whether thermal stimuli are necessary to detect it. In a retrospective study of [18F]FDG (dose not specified) PET scans, Cypress et al 54 detected BAT in 7.5% of women and 3.1% of men studied under thermoneutral conditions. Lichtenbelt et al 64 found that BAT was detected in 23/24 subjects after cold exposure (16°C for 2 hours) but was not detected in 3 of these subjects who were also studied under thermoneutral conditions([18F]FDG dose of 74 MBq). Finally, Virtanen et al 65 reported that BAT was detected in 5/5 adult subjects under both thermoneutral and post-cold exposure (19°C for 2 hours) conditions using a higher dose (185 MBq) of [18F]FDG.

The anatomic identification of BAT in humans using FDG does not necessarily reflect actual thermogenic activity of BAT, and the question remains as to whether BAT actually participates in resting thermogenesis, diet-induced thermogenesis, or adaptive thermogenesis following weight loss or gain in humans. Increased glucose uptake by BAT is considered to reflect increased metabolic activity and thermogenesis 56, 66, 67. This is the basis for the use of the FDG PET technique in localization of tumors and for the analysis of brain areas involved in different cognitive activities as well as for examining myocardial metabolic activity56. Thus, the FDG uptake seen in brown adipose tissue in adult man implies the existence of thermogenically active tissue in adult man. The magnitude of glucose uptake by BAT in FDG PET studies of subjects fasted and at rest, compared to other tissues, also suggests that BAT may play a significant role in glucose disposal in low activity states (i.e., the state in which we spend at least 1/3 of our lives). Assuming that reduced BAT activation following weight loss is a significant factor in adaptive thermogenesis, this effect is more likely to be evident in obligatory than facultative thermogenesis. In this environment we spend almost all of our time in thermoneutral conditions reducing the need for facultative thermogenesis and possibly contributing to the increasing prevalence of obesity 68, 69. Further studies of the role of BAT in human thermogenesis outside of the neonatal period are clearly indicated.

Metabolic responses to attempts to sustain weight gain

The metabolic changes that occur in subjects during maintenance of an elevated body weight following overfeeding involve many of the same systems but are not, in fact, mirror images of the changes following weight loss. In a manner complementary to that seen following weight loss, the maintenance of an elevated body weight is associated with significant increases in circulating concentrations of T3 and T4, SNS tone, TEE, NREE, and, of course, circulating leptin concentrations and a decreases in PNS tone and skeletal muscle work efficiency. However, there is no demonstrable effect of the maintenance of an elevated body weight on circulating concentrations of TSH, and there is a much more marked effect of elevated weight maintenance on TEF and less of an effect on REE than is seen following weight loss11, 36, 70.

Unlike the metabolic opposition to sustaining a reduced body weight, which persists long after weight reduction in mice 71 and humans 72, the increased energy expenditure noted during short-term overfeeding in mice seems to be short-lived. Rodents with diet-induced obesity demonstrate increased energy expenditure 73 and increased SNS tone74 during the first 3–4 weeks of overfeeding. However, after a few months on a high fat diet, these changes are no longer evident 74, 75, indicating that resistance to sustained increased adiposity is less sustained than resistance to decreased adiposity 69. The steadily increasing prevalence of obesity in humans also suggests that body fatness is facilitated more vigorously than body thinness. In addition to the lack of physiological persistence of strong metabolic opposition to weight gain, any “defense” against further weight gain is stretched to the limit by this lifestyle, while opposition to sustaining weight loss remains potent and viable76.

Energy Intake

As noted above, the long-term constancy of body weight suggests that energy intake and expenditure vary coordinately to maintain relatively stable energy stores. This “coupling” which reduces caloric intake in response to decreased energy expenditure is disrupted during and following weight loss 7. During dynamic weight loss, human beings and rodents are both hungrier (willing to eat more often) and less satiated (willing to eat more per meal) 77. Even during maintenance of a reduced weight, satiety remains diminished despite the decline in energy expenditure 78. The simultaneous declines in both energy expenditure and satiety following weight loss conspire to create the optimal biological circumstance for weight regain.

Leptin in Energy Homeostasis

A critical mediator of these reciprocal changes in energy intake and expenditure is the hormone leptin. Leptin is an adipocyte derived molecule that circulates in weight-stable individuals in direct proportion to fat mass 79. The hyperphagic, hypometabolic phenotype of weight-reduced humans is similar to that of leptin-deficient or -unresponsive humans and rodents 80. Circulating leptin concentrations are inversely correlated with hunger ratings in humans during weight loss, independent of the amount of weight or body fat lost 81. Leptin administration reverses the hyperphagia associated with leptin deficiency in leptin-deficient mice and humans 82, 83, and acts synergistically with sibutramine to reduce food intake in rodents 84. Leptin suppresses food intake by promoting the production of anorexigenic neuropeptides (processed products of POMC) and reducing the expression of orexigens such as neuropeptide Y (NPY), agouti-related peptide (AgRP), and melanin concentrating hormone (MCH). Thus, decreased circulating leptin concentrations as a result of reduced fat mass has the net effect of stimulating food intake 1.

The hypothalamic POMC-melanocortin-MC4R pathway is highly sensitive to circulating leptin concentrations and POMC expression is decreased in low-leptin states 29, 85. Briefly, POMC is cleaved to alpha-melanocyte stimulating hormone (α-MSH) and beta-endorphin (β-EP) as well as other bioactive molecules. As discussed previously, α-MSH stimulates release of hypothalamic pro-TRH. β-EP inhibits the release of hypothalamic corticotropin releasing factor (CRF). Therefore, reduced ambient leptin induced by weight loss, should be associated with decreased HPT and increased HPA axis activity. Mice overexpressing the melanocortin 4 receptor (MC4R) antagonists agouti signaling protein (ASP) or agouti-related peptide (AgRP) 86- as well as rodents and humans with hypomorphic mutations in MC4R 87, disruptions of POMC gene expression 88, 89 or of proproneuropeptide (e.g., POMC, pro-ACTH, pro-TRH) processing by prohormone convertases 90, 91 - are obese. The importance of leptin in mediating these effects is reflected in the observation that fasting in rodents causes hypoleptinemia that is associated with increased arcuate and brainstem NPY and AgRP mRNA expression and decreased POMC mRNA in lean animals, but not in leptin-receptor deficient animals 92.

Administration of leptin to leptin-deficient rodents and humans in doses that restore circulating leptin concentrations to their physiological range increases energy expenditure 93, decreases energy intake, increases sympathetic nervous system activity 94, and normalizes hypothalamic-pituitary-adrenal, thyroid, and gonadal function1, 29, 82. Yet, in humans (lean or obese) and rodents who are not leptin-deficient, induction of weight loss requires doses of leptin that produce plasma leptin concentrations over 10 times normal 95, 96. Recent studies of the short-term administration of leptin to weight-reduced lean and obese subjects suggest that restoration of circulating concentrations of leptin to levels present prior to weight loss reverses the decreased energy expenditure, and its associated declines in thyroid hormone and SNS activity and increase in skeletal muscle work efficiency, and increased energy intake, measured behaviorally and by functional magnetic resonance imaging of neuronal responses to food, that characterize the weight-reduced state78, 82, 97. In this sense, the weight-reduced state may be perceived by CNS components relevant to energy homeostasis as a state of relative leptin deficiency. Pharmacotherapy activating the leptin-signaling pathway may help weight-reduced individuals to sustain their weight loss98.

Summary

Attempts to sustain weight loss invoke adaptive responses involving the coordinate actions of metabolic, neuroendocrine, autonomic, and behavioral changes that “oppose” the maintenance of a reduced bodyweight. This phenotype is distinct from that opposing dynamic weight loss per se. The multiplicity of systems regulating energy stores and opposing the maintenance of a reduced body weight illustrate that body energy stores in general and fat stores in particular are actively “defended” by interlocking bioenergetic and neurobiological physiologies. Important inferences can be drawn for therapeutic strategies by recognizing obesity as a state in which the human body actively opposes the “cure” over long periods of time beyond the initial resolution of symptomatology.

References

  • 1.Leibel R, Chua S, Rosenbaum M. Chapter 157. Obesity. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The metabolic and molecular bases of inherited disease. 8. III. New York: McGraw-Hill; 2001. pp. 3965–4028. [Google Scholar]
  • 2.West DB, Boozer CN, Moody DL, Atkinson RL. Dietary obesity in nine inbred mouse strains. Am J Physiol. 1992;262:R1025–R32. doi: 10.1152/ajpregu.1992.262.6.R1025. [DOI] [PubMed] [Google Scholar]
  • 3.Bouchard C, Tremblay A. Genetic influences on the response of body fat and fat distribution to positive and negative energy balances in human identical twins. J Nutr. 1997;127:943S–47S. doi: 10.1093/jn/127.5.943S. [DOI] [PubMed] [Google Scholar]
  • 4.Bouchard C, Tremblay A, Despres JP, Nadeau A, Lupien PJ, Theriault G, et al. The response to long-term overfeeding in identical twins. N Engl J Med. 1990;322:1477–82. doi: 10.1056/NEJM199005243222101. [DOI] [PubMed] [Google Scholar]
  • 5.Rosenbaum M. Epidemiology of pediatric obesity. Ped Annals. 2007;36:89–95. doi: 10.3928/0090-4481-20070201-07. [DOI] [PubMed] [Google Scholar]
  • 6.Lewis C, Jacobs D, McCreath H, Kiefe C, Schreiner P, Smith D, et al. Weight gain continues in the 1990s: 10-year trends in weight and overweight from the CARDIA study. Coronary Artery Risk development in Young Adults. Am J Epidemiol. 2000;151:1172–81. doi: 10.1093/oxfordjournals.aje.a010167. [DOI] [PubMed] [Google Scholar]
  • 7.Moore M. Interactions between physical activity and diet in the regulation of body weight. Proc Nutr Soc. 2000;59:193–98. doi: 10.1017/s0029665100000215. [DOI] [PubMed] [Google Scholar]
  • 8.McGuire M, Wing R, Klem M, Hill J. Behavioral strategies of individuals who have maintained long-term weight losses. Obes Res. 1999;7:334–41. doi: 10.1002/j.1550-8528.1999.tb00416.x. [DOI] [PubMed] [Google Scholar]
  • 9.Wing R, Hill J. Successful weight loss maintenance. Annu Rev Nutr. 2001;21:323–41. doi: 10.1146/annurev.nutr.21.1.323. [DOI] [PubMed] [Google Scholar]
  • 10.Klem M, Wing R, Lang W, McGuire M, Hill J. Does weight loss maintenance become easier over time. Obes Res. 2000;8:438–44. doi: 10.1038/oby.2000.54. [DOI] [PubMed] [Google Scholar]
  • 11.Leibel R, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Eng J Med. 1995;332:621–28. doi: 10.1056/NEJM199503093321001. [DOI] [PubMed] [Google Scholar]
  • 12.Weigle D, Sande K, Iverius P, Monsen E, Brunzell J. Weight loss leads to a marked decrease in nonresting energy expenditure in ambulatory human subjects. Metabolism. 1988;37:930–36. doi: 10.1016/0026-0495(88)90149-7. [DOI] [PubMed] [Google Scholar]
  • 13.Weyer C, Walford R, Harper I, Milner M, MacCallum T, Tataranni P, et al. Energy metabolism after 2 y of energy restriction: the biosphere 2 experiment. Am J Clin Nutr. 2000;72:946–53. doi: 10.1093/ajcn/72.4.946. [DOI] [PubMed] [Google Scholar]
  • 14.Gemert Wv, Westerterp K, Acker Bv, Wagenmakers A, Halliday D, Greve J, et al. Energy, substrate and protein metabolism in morbid obesity before, during and after massive weight loss. Int J Obes. 2000;24:711–18. doi: 10.1038/sj.ijo.0801230. [DOI] [PubMed] [Google Scholar]
  • 15.Leibel R, Hirsch J. Diminished energy requirements in reduced-obese patients. Metabolism. 1984;33:164–70. doi: 10.1016/0026-0495(84)90130-6. [DOI] [PubMed] [Google Scholar]
  • 16.dePeuter R, Withers R, Brinkman M, Tomas F, Clark D. No differences in rates of energy expenditure between post-obese women and their matched, lean controls. Int J Obes. 1992;16:801–08. [PubMed] [Google Scholar]
  • 17.Amatruda J, Statt M, Welle S. Total and resting energy expenditure in obese women reduced to ideal body weight. J Clin Invest. 1993;92:1236–42. doi: 10.1172/JCI116695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Weinsier R, Hunter G, Zuckerman P, Redden D, Darnell B, Larson D, et al. Energy expenditure and free-living physical activity in black and white women: comparison and after weight loss. Am J Clin Nutr. 2000;71:1138–46. doi: 10.1093/ajcn/71.5.1138. [DOI] [PubMed] [Google Scholar]
  • 19.Astrup A, Gotzsche P, Werken Kvd, Ranneries C, Toubro S, Raben A, et al. Meta-analysis of resting metabolic rate in formerly obese subjects. Am J Clin Nutr. 1999;69:1117–22. doi: 10.1093/ajcn/69.6.1117. [DOI] [PubMed] [Google Scholar]
  • 20.Rosenbaum M, Vandenborne K, Goldsmith R, Simoneau J, Heymsfield S, Joanisse D, et al. Effects of experimental weight perturbation on skeletal muscle work efficiency in human subjects. Amer J Physiol. 2003;285:R183–92. doi: 10.1152/ajpregu.00474.2002. [DOI] [PubMed] [Google Scholar]
  • 21.Klem M, Wing R, McGuire M, Seagle H, Hill J. A descriptive study of individuals successful at long term maintenance of substantial weight loss. Am J Clin Nutr. 1998;66:239–46. doi: 10.1093/ajcn/66.2.239. [DOI] [PubMed] [Google Scholar]
  • 22.Newcomer B, Larson-Meyer D, Hunter G, Weinsier R. Skeletal muscle metabolism in overweight and post-overweight women: an isometric exercise study using (31)P magnetic resonance spectroscopy. Int J Obes. 2001;25:1309–15. doi: 10.1038/sj.ijo.0801673. [DOI] [PubMed] [Google Scholar]
  • 23.Pirke K, Briicjs A, Wilckens T, Marquard R, Schweiger U. Starvation induced hyperactivity in the rat: the role of endocrine and neurotransmitter changes. Neurosci Biobehav Rev. 1993;17:287–94. doi: 10.1016/s0149-7634(05)80012-0. [DOI] [PubMed] [Google Scholar]
  • 24.Freyschuss U, Melcher A. Exercise energy expenditure in extreme obewsity: influence of ergometry type and weight loss. Scand J Clin Lab Invest. 1978;38:753–59. doi: 10.1080/00365517809104883. [DOI] [PubMed] [Google Scholar]
  • 25.Walter G, Vandenborne K, McCully K, Leigh J. Noninvasive measurement of PCr recovery kinetics in single human muscles. Am J Physiol. 1997;268:C869–76. doi: 10.1152/ajpcell.1997.272.2.C525. [DOI] [PubMed] [Google Scholar]
  • 26.Blei M, Conley K, Kushmerick M. Separate measures of ATP utilization and recovery in human skeletal muscle. J Physiol (Lond) 1993;465:203–22. doi: 10.1113/jphysiol.1993.sp019673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Goldsmith R, Joanisse D, Gallagher D, Pavlovich K, Shamoon E, Leibel R, et al. Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects. Am J Physiol. 2009 doi: 10.1152/ajpregu.00053.2009. In Press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Schwartz M, Woods S, Porte D, Seeley R, Baskin D. Central nervous system control of food intake. Nature. 2000;404:661–70. doi: 10.1038/35007534. [DOI] [PubMed] [Google Scholar]
  • 29.Wardlaw S. Clinical review 127: Obesity as a neuroendocrine disease: lessons to be learned from proopiomelanocortin and melanocortin receptor mutations in mice and men. J Clin Endocrinol Metab. 2001;86:1442–6. doi: 10.1210/jcem.86.4.7388. [DOI] [PubMed] [Google Scholar]
  • 30.Shimomura Y, Bray GA, Lee M. Adrenalectomy and steroid treatment in obese (ob/ob) and diabetic (db/db) mice. Horm Metab Res. 1987;19:295–99. doi: 10.1055/s-2007-1011804. [DOI] [PubMed] [Google Scholar]
  • 31.Kennedy S, Brown G, McVrey G, Garfinkel P. Pineal and adrenal function before and after refeeding in anorexia nervosa. Biol Psych. 1991;30:216–24. doi: 10.1016/0006-3223(91)90106-v. [DOI] [PubMed] [Google Scholar]
  • 32.Guldstrand M, Ahren B, Wredling R, Backman L, Linus P, Adamson U. Alteration of the counterregulatory responses to insulin-induced hypoglycemia and of cognitive function after massive weight reduction in severely obese subjects. Metabolism. 2003;52:900–07. doi: 10.1016/s0026-0495(03)00103-3. [DOI] [PubMed] [Google Scholar]
  • 33.Yanovski J, Yanovski S, Gold P, Chorousos G. Differences in corticotropin-releasing hormone-stimulated adrenocorticotropin and cortisol before and after weight loss. J Clin Endocrinol Metab. 1997;82:1874–78. doi: 10.1210/jcem.82.6.3998. [DOI] [PubMed] [Google Scholar]
  • 34.Danforth E, Burger A. The role of thyroid hormones in the control of energy expenditure. Clin Endocrinol Metab. 1984;13:581–96. doi: 10.1016/s0300-595x(84)80039-0. [DOI] [PubMed] [Google Scholar]
  • 35.al-Adsani H, Hoffer L, Silva J. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab. 1997;82:1118–25. doi: 10.1210/jcem.82.4.3873. [DOI] [PubMed] [Google Scholar]
  • 36.Rosenbaum M, Hirsch J, Murphy E, Leibel R. The effects of changes in body weight on carbohydrate metabolism, catecholamine excretion, and thyroid function. Amer J Clin Nutr. 2000;71:1421–32. doi: 10.1093/ajcn/71.6.1421. [DOI] [PubMed] [Google Scholar]
  • 37.Goodwin G, Fairburn C, Keenan J, Cowen P. The effects of dieting and weight loss upon the stimulation of thyrotropin (TSH) by thyrotropin-releasing hormone (TRH) and suppression of cortisol secretion by dexamethasone in men and women. J Affect Dis. 1988;14:137–44. doi: 10.1016/0165-0327(88)90056-0. [DOI] [PubMed] [Google Scholar]
  • 38.Guzzaloni G, Grugni G, Moro D, Calo G, Tonelli E, Ardizzi A, et al. Thyroid-stimulating hormone and prolactin responses to thyrotropin-releasing hormone in juvenile obesity before and after hypocaloric diet. J Encodrinol Invest. 1995;18:621–29. doi: 10.1007/BF03349780. [DOI] [PubMed] [Google Scholar]
  • 39.Rosenbaum M, Nicolson M, Hirsch J, Murphy E, Chu F, Leibel R. Effects of weight change on plasma leptin concentrations and energy expenditure. J Clin Endocrinol Metab. 1997;82:3647–54. doi: 10.1210/jcem.82.11.4390. [DOI] [PubMed] [Google Scholar]
  • 40.Fekete C, Legradi G, Mihaly E, Huang Q, Tatro J, Rand W, et al. alpha-Melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. J Neurosci. 2000;20:1550–58. doi: 10.1523/JNEUROSCI.20-04-01550.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Harris M, Aschkenasi C, Elias C, Chandrankunnel A, Nillni E, Bjorbaek C, et al. Transcriptional regulation of the thyrotropin-releasing hormone gene by leptin and melanocortin signaling. J Clin Invest. 2001;107:111–20. doi: 10.1172/JCI10741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Lang C, Rayos G, Chomsky D, Wood A, Wilson J. Effect of sympathoinhibition on exercise performance in patients with heart failure. Circulation. 1997;96:238–45. doi: 10.1161/01.cir.96.1.238. [DOI] [PubMed] [Google Scholar]
  • 43.Aronne L, Mackintosh R, Rosenbaum M, Leibel R, Hirsch J. Autonomic nervous system activity in weight gain and weight loss. Am J Physiol. 1995;38:R222–25. doi: 10.1152/ajpregu.1995.269.1.R222. [DOI] [PubMed] [Google Scholar]
  • 44.Kardos A, Taylor D, Thompson C, Styles P, Hands L, Collin J, et al. Sympathetic denervation of the upper limb improves forearm exercise performance and skeletal muscle bioenergetics. Circulation. 2000;13:2716–20. doi: 10.1161/01.cir.101.23.2716. [DOI] [PubMed] [Google Scholar]
  • 45.Dobbins R, Szczepaniak L, Zhang W, McGarry J. Chemical sympathectomy alters regulation of body weight during prolonged ICV leptin infusion. Am J Physiol. 2003;284:E778–87. doi: 10.1152/ajpendo.00128.2002. [DOI] [PubMed] [Google Scholar]
  • 46.Aronne L, Mackintosh R, Rosenbaum M, Leibel R, Hirsch J. Cardiac autonomic nervous system activity in obese and never-obese young men. Obes Res. 1997;5:354–59. doi: 10.1002/j.1550-8528.1997.tb00564.x. [DOI] [PubMed] [Google Scholar]
  • 47.Kim M, Small C, Stanley S, Morgan D, Seal L, Kong W, et al. The central melanocortin system affects the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin. J Clin Invest. 2000;105:1005–11. doi: 10.1172/JCI8857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Flier J, Harris M, Hollenberg A. Leptin, nutrition, and the thyroid: the why, the wherefore, and the wiring. J Clin Invest. 2000;105:859–61. doi: 10.1172/JCI9725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84:277–359. doi: 10.1152/physrev.00015.2003. [DOI] [PubMed] [Google Scholar]
  • 50.Trayhurn P, Nicholls D, editors. Brown Adipose Tissue. Baltimore, MD: Edward Arnold; 1986. pp. 117–23. [Google Scholar]
  • 51.Leibel R, Berry E, Hirsch J. In vivo evidence for catechol-responsive brown adipose tissue in obese patients. Proceedings Fifth International Congress on Obesity; Jerusalem, Israel. 1987. [Google Scholar]
  • 52.Chemogubova E, Hurchinson D, Nedergaard J, Bengtsson T. Alpha1- and beta1-adrenoceptor signaling fully compensates for beta3-adrenoceptor deficiency in brown adipocyte norepinephrine-stimulated glucose uptake. Endocrinology. 2005;146:2271–84. doi: 10.1210/en.2004-1104. [DOI] [PubMed] [Google Scholar]
  • 53.Alkemade A. Central and peripheral effects of thyroid hormone signalling in the control of energy metabolism. J Neuroendocrinol. 2010;22:56–63. doi: 10.1111/j.1365-2826.2009.01932.x. [DOI] [PubMed] [Google Scholar]
  • 54.Cypress A, Lehman S, Williams G, Tal I, Rodman D, Goldfine A, et al. Identification and importance of brown adipose tissue in adult humans. N Eng J Med. 2009;360:1509–17. doi: 10.1056/NEJMoa0810780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Seale P, Lazar M. Brown fat in humans: turning up the heat on obesity. Diabetes. 2009;68:1482–84. doi: 10.2337/db09-0622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Nedergaard J, Connolly E, Cannon B. Brown adipose tissue in the mammalian neonate. In: Trayhurn P, Nicholls D, editors. Brown Adipose Tissue. Baltimore, MD: Edward Arnold; 1986. pp. 152–213. [Google Scholar]
  • 57.Astrup A, Bulow J, Madsen J, Christensen N. Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man. Am J Physiol. 1985;248:E507–15. doi: 10.1152/ajpendo.1985.248.5.E507. [DOI] [PubMed] [Google Scholar]
  • 58.Nedergard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol. 2007;293:E444–52. doi: 10.1152/ajpendo.00691.2006. [DOI] [PubMed] [Google Scholar]
  • 59.Truong M, Erasmus J, Munden R, Marom E, Sabloff B, Gladish G, et al. Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. Am J Roentgenol. 2004;183:1127–32. doi: 10.2214/ajr.183.4.1831127. [DOI] [PubMed] [Google Scholar]
  • 60.Chib C, Katsuragi I, Simada T, Adachi I, Satoh Y, Noguchi H, et al. Evaluation of human brown adipose tissue using positron emission tomography, computerised tomography and histochemical studies in association with body mass index, visceral fat accumulation and insulin resistance (Abstract) Obes Rev. 2006;7:87. [Google Scholar]
  • 61.Jacobsson H, Bruzelius M, Larsson S. Reduction of FDG uptake in brown adipose tissue by propranolol. Eur J Nucl Mol Imaging. 2005;32:1130. doi: 10.1007/s00259-005-1851-7. [DOI] [PubMed] [Google Scholar]
  • 62.Tatsumi M, Engles J, Ishimori T, Nicely O, Cohade C, Wahl R. Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med. 2004;45:1189–93. [PubMed] [Google Scholar]
  • 63.Soderlund V, Larsson S, Jacobsson H. Reduction of FGD uptake in brown adipose tissue in clinical patients by a single dose of propranolol. Eur J Nucl Med Mol Imaging. 2007;45:1018–22. doi: 10.1007/s00259-006-0318-9. [DOI] [PubMed] [Google Scholar]
  • 64.Lichtenbelt W, Vanjommeng J, Smulders N, Drossaerts J, Kemerink G, Bouvy N, et al. Cold-activated brown adipose tissue in healthy men. N Eng J Med. 2009;360:1500–08. doi: 10.1056/NEJMoa0808718. [DOI] [PubMed] [Google Scholar]
  • 65.Virtanen K, Lidell M, Orava J, Jeglind M, Westergren R, Niemi T, et al. Functional brown adipose tissue in healthy adults. N Eng J Med. 2009;360:1518–25. doi: 10.1056/NEJMoa0808949. [DOI] [PubMed] [Google Scholar]
  • 66.Chernogubova E, Cannon B, Bengtsson T. Norepinephrine increases glucose transport in brown adipocytes via 3-adrenoceptors through a cAMP, PKA and PI3-kinase-dependent pathway stimulating conventional and novel PKCs. Endocrinol. 2004;145:269–80. doi: 10.1210/en.2003-0857. [DOI] [PubMed] [Google Scholar]
  • 67.Marette A, Bukowiecki L. Noradrenaline stimulates glucose transport in rat brown adipocytes by activating thermogenesis. Evidence that fatty acid activation of mitochondrial respiration enhances glucose transport. Biochem J. 1991;277:119–24. doi: 10.1042/bj2770119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Elobeid M, Allison D. Putative environmental-endocrine disruptors and obesity: a review. Curr Opin Endocrinol Diabetes Obes. 2008;15:403–08. doi: 10.1097/MED.0b013e32830ce95c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Schwartz M, Woods S, Seeley R, Barsh G, Baskin D, Leibel R. Is the energy homeostasis system inherently biased toward weight gain? Diabetes. 2003;52:232–38. doi: 10.2337/diabetes.52.2.232. [DOI] [PubMed] [Google Scholar]
  • 70.Tremblay A, Despres J, Theriault G, Fournier G, Bouchard C. Overfeeding and energy expenditure in humans. Am J Clin Nutr. 1992;56:857–62. doi: 10.1093/ajcn/56.5.857. [DOI] [PubMed] [Google Scholar]
  • 71.Dulloo A, Girardier L. 24 hour energy expenditure several months after weight loss in the underfed rat: evidence for a chronic decrease in whole-body metabolic efficiency. Int J Obes. 1993;17:115–23. [PubMed] [Google Scholar]
  • 72.Rosenbaum M, Hirsch J, Gallagher D, Leibel R. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Amer J Clin Nutr. 2008;88:906–12. doi: 10.1093/ajcn/88.4.906. [DOI] [PubMed] [Google Scholar]
  • 73.Rothwell N, Stock M. Energy expenditure of cafeteria-fed rats determined from measurements of energy balance and indirect calorimetry. J Physiol London. 1982;328:371–77. doi: 10.1113/jphysiol.1982.sp014270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Levin BE, Triscari J, Sullivan AC. Altered sympathetic activity during development of diet-induced obesity in rat. Am J Physiol. 1983;244:R347–R55. doi: 10.1152/ajpregu.1983.244.3.R347. [DOI] [PubMed] [Google Scholar]
  • 75.Corbett SW, Stern JS, Keesey RE. Energy expenditure in rats with diet-induced obesity. Am J Clin Nutr. 1986;44:173–80. doi: 10.1093/ajcn/44.2.173. [DOI] [PubMed] [Google Scholar]
  • 76.Murgatroyd P, Goldberg G, Leahy F, Prentice A. Effects of inactivity and diet composition on human energy balance. Int J Obes. 1999;23:1269–75. doi: 10.1038/sj.ijo.0801062. [DOI] [PubMed] [Google Scholar]
  • 77.Doucet E, Cameron J. Appetite control after weight loss: what is the role of bloodborne peptides? Amer J Physiol Nutr Metab. 2007;32:523–32. doi: 10.1139/H07-019. [DOI] [PubMed] [Google Scholar]
  • 78.Kissileff H, Thornton M, Torres M, Pavlovich K, Leibel R, Rosenbaum M. Maintenance of reduced body weight in humans is associated with leptin-reversible declines in satiation. 2010 (submitted) [Google Scholar]
  • 79.Rosenbaum M, Nicolson M, Hirsch J, Heymsfield S, Gallagher D, Chu F, et al. Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab. 1996;81:3424–27. doi: 10.1210/jcem.81.9.8784109. [DOI] [PubMed] [Google Scholar]
  • 80.Leibel R. The role of leptin in the control of body weight. Nutr Rev. 2002;60:S15–19. doi: 10.1301/002966402320634788. [DOI] [PubMed] [Google Scholar]
  • 81.Heini A, Lara-Castro C, Kirk K, Considine R, Caro J, Weinsier R. Association of leptin and hunger-satiety ratings in obese women. Int J Obes. 1998;22:1084–87. doi: 10.1038/sj.ijo.0800731. [DOI] [PubMed] [Google Scholar]
  • 82.Farooqi I, Jebb S, Langmack G, Lawrence E, Cheetham C, Prentice A, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Eng J Med. 1999;341:879–84. doi: 10.1056/NEJM199909163411204. [DOI] [PubMed] [Google Scholar]
  • 83.Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995;269:546–49. doi: 10.1126/science.7624778. [DOI] [PubMed] [Google Scholar]
  • 84.Boozer C, Love R, Cha M, Leibel R, Aronne L. Synergy of leptin and sibutramine in treatment of diet-induced obesity in rats. Metabolism. 2001;50:889–93. doi: 10.1053/meta.2001.24917. [DOI] [PubMed] [Google Scholar]
  • 85.Korner J, Chua S, WIlliams J, Leibel R, Wardlaw S. Regulation of hypothalamic pro-opiomalanocortin by lean and obese rats. Neuroendocrinol. 1999;70:377–83. doi: 10.1159/000054499. [DOI] [PubMed] [Google Scholar]
  • 86.Ollmann M, Wilson B, Yang Y, Kerns J, Chen Y, Barsh G. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science. 1997;278:135–38. doi: 10.1126/science.278.5335.135. [DOI] [PubMed] [Google Scholar]
  • 87.Farooqi I, Keogh J, Yeo G, Lank E, Ceetham T, O’Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Eng J Med. 2003;348:1085–95. doi: 10.1056/NEJMoa022050. [DOI] [PubMed] [Google Scholar]
  • 88.Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency, and red hair pigmentation caused by POMC nutations in humans. Nat Genet. 1998;19:155–57. doi: 10.1038/509. [DOI] [PubMed] [Google Scholar]
  • 89.Yaswen L, Diehl N, Brennan M, Hochgeswender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med. 1999;5:1066–70. doi: 10.1038/12506. [DOI] [PubMed] [Google Scholar]
  • 90.Naggert JK, Fricker LD, Varlamov O, Nishin RM, Rouille T, Steiner DF, et al. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nature Genet. 1995;10:135–42. doi: 10.1038/ng0695-135. [DOI] [PubMed] [Google Scholar]
  • 91.Jackson RS, Creemers JWM, Ohagi S, Raffin-Sanson M-L, Sanders L, Montague CT, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nature Genetics. 1997;16:303. doi: 10.1038/ng0797-303. [DOI] [PubMed] [Google Scholar]
  • 92.Korner J, Wardlaw S, Liu S, Conwell I, Leibel R, Chua S. Effects of leptin receptor mutation on Agrp gene expression in fed and fasted lean and obese (LA/N-faf) rats. Endocrinol. 2000;141:2465–71. doi: 10.1210/endo.141.7.7580. [DOI] [PubMed] [Google Scholar]
  • 93.Solinas G, Summermatter S, Mainieri D, Gubler M, Pirola L, Wymann M, et al. The direct effect of leptin on skeletal muscle thermogenesis is mediated by substrate cycling between de novo lipogenesis and lipid oxidation. Febs. 2004;577:539–44. doi: 10.1016/j.febslet.2004.10.066. [DOI] [PubMed] [Google Scholar]
  • 94.Satoh N, Ogawa Y, Katsuura G, Numata Y, Tsuji T, Hayase M, et al. Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion. Diabetes. 1999;48:1787–93. doi: 10.2337/diabetes.48.9.1787. [DOI] [PubMed] [Google Scholar]
  • 95.Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial. JAMA. 1999;292:1568–75. doi: 10.1001/jama.282.16.1568. [DOI] [PubMed] [Google Scholar]
  • 96.Campfield L, Smith F, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995;269:546–48. doi: 10.1126/science.7624778. [DOI] [PubMed] [Google Scholar]
  • 97.Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A, Weimer L, Heymsfield S, et al. Low dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest. 2005;115:3579–86. doi: 10.1172/JCI25977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Ravussin E, Smith S, Mitchell J, Shringarpure R, Shan K, Maier H, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity. 2009;17:1736–43. doi: 10.1038/oby.2009.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Welt C, Chan J, Bullen J, Murphy R, Smith P, DePaoli A, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Eng J Med. 2004;351:987–97. doi: 10.1056/NEJMoa040388. [DOI] [PubMed] [Google Scholar]

RESOURCES